KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Return on Sales (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Return on Sales for 18 consecutive years, with 0.2% as the latest value for Q1 2026.

  • For Q1 2026, Return on Sales fell 7.0% year-over-year to 0.2%; the TTM value through Mar 2026 reached 0.3%, down 2.0%, while the annual FY2025 figure was 0.31%, 0.0% changed from the prior year.
  • Return on Sales hit 0.2% in Q1 2026 for Regeneron Pharmaceuticals, down from 0.22% in the prior quarter.
  • Across five years, Return on Sales topped out at 19.47% in Q1 2022 and bottomed at 0.2% in Q1 2026.
  • Average Return on Sales over 5 years is 2.12%, with a median of 0.31% recorded in 2023.
  • Year-over-year, Return on Sales skyrocketed 1903bps in 2022 and then plummeted -1921bps in 2023.
  • Regeneron Pharmaceuticals' Return on Sales stood at 11.97% in 2022, then plummeted by -97bps to 0.34% in 2023, then dropped by -28bps to 0.24% in 2024, then fell by -10bps to 0.22% in 2025, then decreased by -7bps to 0.2% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.2%, 0.22%, and 0.39% for Q1 2026, Q4 2025, and Q3 2025 respectively.